<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02025036</url>
  </required_header>
  <id_info>
    <org_study_id>FirstHenanUST</org_study_id>
    <nct_id>NCT02025036</nct_id>
  </id_info>
  <brief_title>Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer</brief_title>
  <acronym>CRTCOESC</acronym>
  <official_title>Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Henan University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Luoyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Military 150 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anyang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Oncology Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Xinyang Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanmenxia Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Henan University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A three-arm Phase III trial was started in Oct. 2014. Definitive chemoradiotherapy with
      cisplatin plus 5-fluorouracil is the standard in Western countries in esophagus cancer. But
      in China because of its toxic reaction, most of patients stop the halfway. Because low
      toxicity, the chemotherapy regimen of capecitabine with or without oxaliplatin are widely
      used in clinical.

      The purpose of this study is to confirm the difference of Capecitabine plus with or without
      oxaliplatin over cisplatin plus 5-fluorouracil with definitive chemoradiotherapy for
      esophagus squamous cell carcinoma. A total of 630 patients will be accrued from China within
      2 years. The primary endpoint is overall survival and the secondary endpoints include
      progression-free survival, response rate, pathologic complete response rate and adverse
      events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We plan to recruit the patients who were pathologically confirmed with esophageal squamous
      cell carcinoma from the Oct 2014. The patients will be divided into three groups.Experimental
      group 1 : single drug Capecitabine and concurrent radiotherapy.Experimental group 2:
      Capecitabine plus oxaliplatin and concurrent radiotherapy. Control group:cisplatin plus
      5-fluorouracil and concurrent radiotherapy. To evaluate the overall survival of the three
      group. Also observe the patient's progression-free survival, response rate, pathologic
      complete response rate and adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade 3/4 acute toxicities</measure>
    <time_frame>90 days</time_frame>
    <description>Grade 3/4 acute toxicities occurred during or within 90 days after RT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>2 years</time_frame>
    <description>Progression Free Survival After completion of the radiation and consolidate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>2 years</time_frame>
    <description>Progression Free Survival After completion of the radiation and consolidate chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall remission rate, ORR</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life, Qol</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathologic complete response rate</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">630</enrollment>
  <condition>Stage III Esophageal Squamous Cell Carcinoma</condition>
  <condition>Stage II Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Capecitabine-oxaliplatin-radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oxaliplatin：65mg/m2，d1，8，22, 29,I.V.or d1, 8, 22, 29, 43, 50, 64, 71,I.V.plus,capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks or 12 weeks in total.
radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cisplatin with 5-FU and radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85, 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.
radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine and radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks or 12 weeks in total, radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine(Aibin)</intervention_name>
    <description>capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total</description>
    <arm_group_label>Capecitabine-oxaliplatin-radiotherapy</arm_group_label>
    <arm_group_label>Capecitabine and radiotherapy</arm_group_label>
    <other_name>Aibin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin(Aiheng)</intervention_name>
    <description>Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.</description>
    <arm_group_label>Capecitabine-oxaliplatin-radiotherapy</arm_group_label>
    <other_name>Aiheng</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity</description>
    <arm_group_label>Capecitabine-oxaliplatin-radiotherapy</arm_group_label>
    <arm_group_label>cisplatin with 5-FU and radiotherapy</arm_group_label>
    <arm_group_label>Capecitabine and radiotherapy</arm_group_label>
    <other_name>Radiation Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-75years old

          -  Histologically proven squamous cell carcinoma of the esophagus the tumor was in
             T2-4N0-2M0

          -  The patients have not received the surgery or chemo-radiotherapy.

          -  Hb≥80g/L, absolute neutrophil count ≥1.5×109/L, Plt≥90×109/L,

          -  ALT、AST≤2.5*N,Cr≤1.5*N.

          -  performance status score 0-2

        Exclusion Criteria:

          -  pregnant, lactating women

          -  Oxaliplatin or fluorouracil Allergy or metabolic disorders

          -  Radiotherapy contraindications

          -  History of organ transplantation

          -  Brain metastasis

          -  The peripheral nervous system disorders

          -  Severe infection

          -  Oral capecitabine who have difficulty with,such as dysphagia,The activities of
             digestive ulcer, Gastrointestinal bleeding

          -  Severe chronic diseases, such as, hepatopathy, nephropathy, respiratory disease,high
             blood pressure, diabetes.

          -  Other malignant tumor in recent 5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shegan Gao, M.D Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tanyou Shan, M.D M.S</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaoshan Feng, M.D Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiachun Sun, M.D Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xinshuai Wang, M.D Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guoqiang Kong, M.D M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaozhi Yuan, M.D M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruinuo Jia, M.D M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Zhou, M.D M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jing Ren, M.D M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruina Yang, M.D M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Wang, M.D M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wei Wang, M.D M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yali Zhang, M.D M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yongxuan Liu, M.D M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Weijiao Yin, M.D M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shiyuan Song, M.D M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guobao Zheng, M.D Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>No. 150 Central Hospital of the Chinese People Liberation Army</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daoke Yang, M.D M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianhua Wang, M.D Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Tumor Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fuyou Zhou, M.D Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anyang Tumour Hospital of Henan province</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nengchao Wang, M.D M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anyang Tumour Hospital of Henan province</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anping Zheng, M.D M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anyang Tumour Hospital of Henan province</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhanhui Miao, M.D M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated Hospital of Xinxiang Medical University, Henan province</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruiwen Zhang, M.D M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinxiang Central Hospital of Henan province</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shegan Gao, M.D Ph.D</last_name>
    <phone>18638859977</phone>
    <email>gsg112258@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tanyou Shan, M.D M.S</last_name>
    <phone>18537976669</phone>
    <email>shantanyou@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shegan Gao, M.D Ph.D</last_name>
      <phone>+86(379)64811906</phone>
      <email>gsg112258@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Tanyou Shan, master</last_name>
      <phone>+86(379)64815350</phone>
      <email>shantanyou@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dan Zhou, M.D.M.S</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Park JW, Kim JH, Choi EK, Lee SW, Yoon SM, Song SY, Lee YS, Kim SB, Park SI, Ahn SD. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):691-7. doi: 10.1016/j.ijrobp.2010.06.041. Epub 2010 Oct 1.</citation>
    <PMID>20888705</PMID>
  </reference>
  <reference>
    <citation>Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.</citation>
    <PMID>23335087</PMID>
  </reference>
  <reference>
    <citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.</citation>
    <PMID>25651787</PMID>
  </reference>
  <reference>
    <citation>Blum MA, Taketa T, Sudo K, Wadhwa R, Skinner HD, Ajani JA. Chemoradiation for esophageal cancer. Thorac Surg Clin. 2013 Nov;23(4):551-8. doi: 10.1016/j.thorsurg.2013.07.006. Review.</citation>
    <PMID>24199704</PMID>
  </reference>
  <reference>
    <citation>Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014 Mar;15(3):305-14. doi: 10.1016/S1470-2045(14)70028-2. Epub 2014 Feb 18. Erratum in: Lancet Oncol. 2014 Dec;15(13):e587.</citation>
    <PMID>24556041</PMID>
  </reference>
  <reference>
    <citation>Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, Takiuchi H, Komatsu Y, Miyata Y, Fukuda H; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (JCOG). Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):684-90. doi: 10.1016/j.ijrobp.2010.06.033. Epub 2010 Oct 6.</citation>
    <PMID>20932658</PMID>
  </reference>
  <reference>
    <citation>Kato K, Nakajima TE, Ito Y, Katada C, Ishiyama H, Tokunaga SY, Tanaka M, Hironaka S, Hashimoto T, Ura T, Kodaira T, Yoshimura K. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma. Jpn J Clin Oncol. 2013 Jun;43(6):608-15. doi: 10.1093/jjco/hyt048. Epub 2013 Apr 12.</citation>
    <PMID>23585687</PMID>
  </reference>
  <reference>
    <citation>Lee SJ, Ahn BM, Kim JG, Sohn SK, Chae YS, Moon JH, Lee EB, Kim JC, Park IK, Jeon SW. Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study. J Korean Med Sci. 2009 Feb;24(1):120-5. doi: 10.3346/jkms.2009.24.1.120. Epub 2009 Feb 28.</citation>
    <PMID>19270824</PMID>
  </reference>
  <reference>
    <citation>Xing L, Liang Y, Zhang J, Wu P, Xu D, Liu F, Yu X, Jiang Z, Song X, Zang Q, Wang W. Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer. J Cancer Res Clin Oncol. 2014 May;140(5):867-72. doi: 10.1007/s00432-014-1615-5. Epub 2014 Mar 1.</citation>
    <PMID>24578238</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2013</study_first_submitted>
  <study_first_submitted_qc>December 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2013</study_first_posted>
  <last_update_submitted>July 2, 2016</last_update_submitted>
  <last_update_submitted_qc>July 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemoradiotherapy， Esophageal Squamous Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

